ENGLEWOOD, Colo., November 30, 2017 — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the engagement of LaVoieHealthScience for their services in investor and public relations. LaVoieHealthScience will immediately begin designing and executing a strategic communications plan to extend Ampio’s reach. Ampio’s lead product candidate, Ampion™, is currently in a Phase 3 clinical trial. Ampion is a novel biologic and is a low molecular weight ultra-filtrate of human serum albumin (HSA), designed for the treatment of signs and symptoms of severe osteoarthritis of the knee (OAK).
LaVoieHealthScience, an integrated investor and public relations agency focused on advancing health and science innovations, will be supporting Ampio in their strategic communications with a broad range of audiences including media, healthcare professionals, the investment community and others. LaVoieHealthScience will use their 16 years of proven industry tactics to help Ampio extend visibility and optimize value.
“As we continue to move forward with Ampion, we believe this is the right time to engage with a strategic communications firm and LHS is the right choice given their deep industry experience,” said Michael Macaluso, Chairman and Chief Executive Officer, Ampio Pharmaceuticals. “We look forward to working with the LaVoieHealthScience team.”
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 29 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients, and is ranked among the 2017 Inc. 5000 list of fastest growing private companies for the fourth year.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements also include the Company’s communications plan, strategies moving forward and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Chief Financial Officer
Phone: (720) 437-6500